Preview

Онкоурология

Расширенный поиск

Эффективность сунитиниба у больных диссеминированным почечно-клеточным раком

https://doi.org/10.17650/1726-9776-2008-4-1-25-28

Полный текст:

Об авторах

О. Б. Карякин
ГУ МРНЦ РАМН
Россия
Обнинск


А. М. Попов
ГУ МРНЦ РАМН
Россия
Обнинск


Список литературы

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2005 году (заболеваемость и смертность). М.; 2007.

2. Novick A.C., Campbell S.C. Renal tumors. In: P.C. Walsh, A.B. Retik, E.D. Vaughan et al. Campbell`s Urology. Philadelphia, WB Saunders; 2002. p. 2672—731.

3. Guida M., Colucci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol 2007;(Suppl 6):149—52.

4. Chow L.Q.M., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884—96.

5. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530—40.

6. De Mulder P., Patard J.-J., Szczylik C. et al. Current status of targeted therapy in metastatic renal cell carcinoma. Eur Urol 2007;6(10):665—71.

7. Motzer R.J., Michaelson M.D., Redman B.G. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16—24.

8. Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516—24.

9. Rosenberg J.E., Motzer R.J., Michaelson M.D. et al. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival. ASCO 2007;abstr 5095.

10. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon-alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115—24.

11. Motzer R.J., Figlin R.A., Hutson T.E. et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. ASCO 2007;abstr 5024.

12. Gore M.E., Porta C., Oudard S. et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assesment of toxicity in an expanded access trial with subpopulation analysis. ASCO 2007;abstr 5010.

13. Remak E., Mullins C.D., Akobundu E. et al. Economic evaluations of sunitinib versus interferon-alfa (IFN ) in first-line metastatic renal cell carcinoma (mRCC). ASCO 2007;abstr 6607.

14. Feldman D.R., Kondagunta G.V., Ronnen E.A. et al. Phase I trial of bevacisumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO 2007;abstr 5099.

15. Kondagunta G.V., Hudes G.R., Figlin R. et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study. ASCO 2007;abstr 5101.

16. Patel P.H., Kondagunta G.V., Redman B.G. et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO 2007;abstr 5097.

17. George D.J., Michaelson M.D., Rosenberg J.E. et al. Phase II trial of sunitinib in bevacisumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. ASCO 2007;abstr 5035.

18. Sablin M.P., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. ASCO 2007;abstr 5038.

19. Dham A., Dudek A.Z. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. ASCO 2007;abstr 5106.

20. Plantade A., Choueiri T., Escudier B. et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. ASCO 2007;abstr 5037.

21. Hutson T.E., Figlin R.A. Evolving role of novel targeted agents in renal cell carcinoma. Oncology 2007;21:1175—80.

22. Escudier B., Koralewski P., Pluzanska A. et al. A randomized, controlled, doubleblind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon-2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007;25(18S):abstr 3.


Для цитирования:


Карякин О.Б., Попов А.М. Эффективность сунитиниба у больных диссеминированным почечно-клеточным раком. Онкоурология. 2008;4(1):25-28. https://doi.org/10.17650/1726-9776-2008-4-1-25-28

For citation:


Karyakin O.B., Popov A.M. Sunitinib efficacy in patients with disseminated renal cell carcinoma. Cancer Urology. 2008;4(1):25-28. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-1-25-28

Просмотров: 16


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X